Assembly Biosciences

ASMB (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Assembly Biosciences, Inc. is a biotechnology company developing antiviral therapeutics worldwide. Its pipeline includes long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 (Phase 1 for recurrent genital herpes) and ABI-6250, an oral HDV entry inhibitor in Phase 1a for chronic HDV. It also studies ABI-4334 (oral capsid assembly modulator, Phase 1b for chronic HBV) and ABI-7272 (oral broad-spectrum NNPI for transplant-associated herpesviruses). The company has an R&D option, license, and collaboration with Gilead. Based in South San Francisco, CA; incorporated in 2005.

Company score

Sentiment: 0.34; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.12; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.02; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.04; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.19; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive